At the core of our innovation is a breakthrough fermentation platform. By eliminating the need for costly sterile conditions, we slash both CAPEX and OPEX, unlocking biomanufacturing at a scale and cost point that radically shifts what’s possible for biological production.
We enable industrial-scale manufacturing of fuels and chemicals that not only reduce emissions but also work seamlessly with existing infrastructure and global supply chains.
Discover more about C3 Biotech in our latest video 
C3 applies the principles of engineering and generative biology — the design, evolution, and engineering of robust microbial strains — to create high-yield production systems tailored for real-world conditions.
Our strains are built to thrive in non-sterile, low-cost environments, transforming industrial waste streams, including CO₂, into high-value commodity products. This enables both the circular reuse of carbon and the production of novel, sustainable chemicals at commercially viable yields.
By combining biology, chemistry, and process engineering, we’re delivering drop-in alternatives to petrochemicals and creating entirely new products not currently accessible through fossil routes — all while de-risking scale-up for commercial readiness.
Our mission is to make sustainable biomanufacturing competitive, scalable, and economically viable — enabling a global shift away from fossil feedstocks toward renewable carbon inputs.
C3’s biological production platforms are designed for:
Our products are made from waste carbon and industrial byproducts, forming the basis of low-carbon and circular chemical value chains.
C3’s platform technologies are designed for flexibility and compatibility across global industrial sectors:
Our low-cost, scalable solutions enable widespread adoption — especially in industries that rely on high-volume carbon-based inputs and require plug-and-play integration.
Read More
C3’s rapid progress is driven by a collaborative innovation model.
We partner with:
Together, these partnerships form an agile and deeply integrated development ecosystem that accelerates our technologies from lab to pilot to commercial scale — ensuring readiness for global deployment.
C3 Biotech is redefining what’s possible with biology. Through breakthrough technology and collaborative innovation, we are enabling a new generation of sustainable, high-performance industrial products — at a cost the world can afford.
Join us in building the next industrial revolution — powered by biology.
Read MoreFounded by Nigel Scrutton and industrialist Michael Smith.
Spun out from the Manchester Institute of Biotechnology to commercialise breakthrough waste-to-fuel research.
Secured £20M+ in competitive funding from the UK MoD and US DoD.
Developed extensive IP portfolio and foundational white papers.
Strategic growth initiated with the recruitment of senior industrial leaders to drive C3’s commercial development and growth.
The Manchester Institute of Biotechnology, C3’s founding research partner, is awarded the Queen’s Anniversary Prize for excellence in biotechnological innovation — recognising, in part, the breakthrough technologies now being scaled by C3 Biotechnologies.
Begins industrial-scale collaborations with Manchester Organics, BioProcess Facility (Delft), Otto Simon, and Zenito.
First RAF drone flight powered by C3's sustainable fuels.
Launches UK pilot plant for sustainable kerosene in Stockport with UK and US funding support.
Wins multiple rounds of the prestigious SPRIND Circular Biomanufacturing Challenge alongside SME partners Chromition, Otto-Simon and Northern Engineering Solutions.
Files 8th family of patents, bringing the total portfolio to 30 awarded and pending patents.
Secures a landmark partnership with a global corporate for bio-based chemicals manufacture.
C3 is featured in UK government foresight reports on next-generation manufacturing.
Keep up to date with the latest news from the C3 team.
